Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7575748 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates

Patent 7575748 was granted and assigned to Genentech on August, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Sharon Erickson0

Ralph Schwall0

Walter Blattler0

Mark Sliwkowski0

Date of Patent

August 18, 2009

Patent Application Number

11488545

Date Filed

July 17, 2006

Patent Citations Received

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 11654105 Subcutaneous HER2 antibody formulations

0

US Patent 11655305 Treatment of metastatic breast cancer

0

US Patent 11744900 Preparation of maytansinoid antibody conjugates by a one-step process

US Patent 11788066 Antibody conjugates and methods of making and using the same

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

0

Patent Primary Examiner

Patent abstract

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7575748 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool